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Blocking Sodium-Taurocholate 
Cotransporting Polypeptide Stimulates 
Biliary Cholesterol and Phospholipid 
Secretion in Mice
Reinout L.P. Roscam Abbing,1* Davor Slijepcevic,1* Joanne M. Donkers,1 Rick Havinga,2 Suzanne Duijst,1 Coen C. Paulusma,1,3 
Johan Kuiper,4 Folkert Kuipers,2 Albert K. Groen ,2,5 Ronald P.J. Oude Elferink,1,3 and Stan F.J. van de Graaf 1,3
Active secretion of bile salts into the canalicular lumen drives bile formation and promotes biliary cholesterol and 
phospholipid output. Disrupting hepatic bile salt uptake, by inhibition of sodium-taurocholate cotransporting polype-
tide (NTCP; Slc10a1) with Myrcludex B, is expected to limit bile salt f lux through the liver and thereby to decrease 
biliary lipid excretion. Here, we show that Myrcludex B–mediated NTCP inhibition actually causes an increase in 
biliary cholesterol and phospholipid excretion whereas biliary bile salt output and bile salt composition remains 
unchanged. Increased lysosomal discharge into bile was excluded as a potential contributor to increased biliary lipid 
secretion. Induction of cholesterol secretion was not a consequence of increased ATP-binding cassette subfamily G 
member 5/8 activity given that NTCP inhibition still promoted cholesterol excretion in Abcg8−/− mice. Stimulatory 
effects of NTCP inhibition were maintained in Sr-b1−/− mice, eliminating the possibility that the increase in biliary 
lipids was derived from enhanced uptake of high-density lipoprotein–derived lipids. NTCP inhibition shifts bile salt 
uptake, which is generally more periportally restricted, toward pericentral hepatocytes, as was visualized using a 
f luorescently labeled conjugated bile salt. As a consequence, exposure of the canalicular membrane to bile salts was 
increased, allowing for more cholesterol and phospholipid molecules to be excreted per bile salt. Conclusion: NTCP 
inhibition increases biliary lipid secretion, which is independent of alterations in bile salt output, biliary bile salt 
hydrophobicity, or increased activity of dedicated cholesterol and phospholipid transporters. Instead, NTCP inhibi-
tion shifts hepatic bile salt uptake from mainly periportal hepatocytes toward pericentral hepatocytes, thereby increas-
ing exposure of the canalicular membrane to bile salts linking to increased biliary cholesterol secretion. This process 
provides an additional level of control to biliary cholesterol and phospholipid secretion. (Hepatology 2019;0:1-12).
Bile formation is driven by active secretion of bile salts from hepatocytes into the canalic-ular lumen by the bile salt export pump.(1) 
Biliary bile salts can be derived from de novo syn-
thesis in the liver or from reuptake of intestine- 
derived bile salts from the portal circulation, a 
process that is mediated primarily by the sodium- 
taurocholate cotransporting polypeptide (NTCP) 
and organic anion transporting proteins (OATPs).(2) 
Hepatobiliary secretion of bile salts promotes biliary 
phospholipid and cholesterol output,(3) and changes 
in bile salt secretion are therefore usually paralleled 
Abbreviations: ABCB4, ATP-binding cassette subfamily B member 4; ABCG5/8, ATP-binding cassette subfamily G member 5/8; ATP11C, 
ATPase phospholipid transporting 11C; BW, body weight; HBV, hepatitis B virus; HDL, high-density lipoprotein; hOATP1B1, human OATP1B1; 
NTCP, sodium-taurocholate cotransporting polypeptide; OATP, organic anion transporting protein; SR-B1, scavenger receptor class B type 1; TC, 
taurocholate; WT, wild type.
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by similar changes in biliary phospholipid and cho-
lesterol output.(4) The latter provides an important 
elimination route for excess body cholesterol.(3)
Recently, it has been shown that NTCP is the 
entry receptor for the hepatitis B virus (HBV), 
which has led to the development of drugs target-
ing NTCP.(5,6) The drug Myrcludex B binds selec-
tively to NTCP, thereby inhibiting HBV entry 
into hepatocytes, and it is currently being tested 
as treatment for chronic HBV/hepatitis delta virus 
infection in a phase 2 trial.(6,7) NTCP inhibition by 
Myrcludex B has also been demonstrated to inhibit 
the physiological function of NTCP, namely bile 
salt transport.(8) As such, Myrcludex B is a potent 
tool to investigate the physiological consequences 
of interrupting enterohepatic cycling of bile salts 
by targeting hepatic bile salt (re)uptake. Previously, 
we have already shown that NTCP inhibition by 
Myrcludex B reduces cholestatic liver injury in mice 
by lowering the bile salt load on the liver and alter-
ing the phospholipid to bile salt ratio in bile, thereby 
reducing bile salt toxicity.(9)
In this study, we set out to evaluate whether 
NTCP inhibition by Myrcludex B specifically affects 
the bile formation process and hepatobiliary output 
of major bile components in healthy, noncholestatic 
mice. Surprisingly, NTCP inhibition increased biliary 
phospholipid and cholesterol output, whereas output 
of endogenous bile salts remained unaffected. Upon 
exclusion of known parameters that could explain this 
remarkable increase of phospholipid and cholesterol 
secretion relative to that of bile salts, we propose that 
NTCP inhibition leads to a shift in hepatic bile salt 
uptake from periportal to pericentral zones of the 
liver. This shift in zonated bile salt uptake enforces 
bile-salt–induced biliary lipid secretion by prolonging 
exposure of the bile canalicular membrane domain to 
the stimulatory actions of bile salts.
Materials and Methods
aNIMal eXpeRIMeNtS
Wild-type (WT) and Abcg8−/− mice (C57BL/6J 
background) were bred and housed in the University 
Medical Center Groningen, Groningen. Sr-bI−/− mice 
(C57BL/6J background) were bred and housed in 
the Gorlaeus Laboratories of the Leiden Academic 
Center for Drug Research, Leiden. ATPase phos-
pholipid transporting 11C (Atp11c)-deficient mice 
(kindly provided by Drs. B. Beutler and O. Siggs)(10) 
were bred and housed in the Amsterdam University 
Medical Centers, Amsterdam. The human OATP1B1 
(hOATP1B1) Oatp1a/1b−/− mice were purchased 
from Taconic (Silkeborg, Denmark) and housed at 
the Amsterdam University Medical Centers. All 
mice used were male. Mice received single subcuta-
neous injections with Myrcludex B (2.5 µg/g body 
weight [BW]) or vehicle. One hour after Myrcludex 
B or vehicle administration, bile duct cannulation 
was performed using a PE-10 catheter, as described 
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in a previous work.(11) Bile was collected in aliquots 
every 10 minutes for a total of 60 minutes (Sr-bI−/− 
mice, WT C57BL/6J mice, and Abcg8−/− mice). 
Taurocholate (TC) infusion and bile collection in 
Atp11c-deficient mice was performed as described.(12) 
Bile flow was determined gravimetrically assuming a 
density of 1 g/mL for bile. A heating pad maintained 
body temperature at 37°C. For visualization of bile salt 
uptake in vivo, WT C57BL/6J mice were purchased 
from Envigo (Venray, the Netherlands) and Ntcp−/− 
were bred and housed at the Amsterdam University 
Medical Centers. WT and Ntcp−/− mice (C57BL/6J) 
received 62.5 nmol of tauro-nor-hyocholic acid-24-
DBD (GenoMembrane, Kanagawa, Japan) in a vol-
ume of 100 µL of NaCl 0.9% by the portal vein. WT 
mice were injected with vehicle or Myrcludex B (2.5 
µg/g BW) before injection of the fluorescent bile salt. 
Five minutes after administration of tauro-nor-HCA-
24-DBD, the liver was harvested. Mice were random-
ized to treatment using online randomization software, 
and investigators were blinded for treatments. Organs 
were snap-frozen in liquid N2 and stored at –80°C 
for further analysis. The study design and all proto-
cols for animal care and handling were approved by 
the Institutional Animal Care and Use Committee 
of the University of Amsterdam (WT C57BL/6J, 
hOATP1B1 Oatp1a/1b−/−, Atp11C−/−, and Ntcp−/−), 
Leiden University (Sr-bI−/−), and the University of 
Groningen (WT C57BL/6J and Abcg8−/−).
MICRoSCopy aND IMagINg oF 
BIle Salt UptaKe
Livers of mice injected with tauro-nor-HCA-24-
DBD were cut in sections of 6 μm on a Leica CM 
1950 cryostat at −20°C. Sections were mounted on 
slides with Vectamount (H-5000, Vector Laboratories, 
Burlingame, CA). Images were obtained with a Leica 
DM-6000B microscope.
WeSteRN BlottINg
Crude mouse liver membranes were isolated as 
described in a previous work.(2) Proteins were trans-
ferred by wet blotting to polyvinylidene difluoride 
membrane and probed with antimouse scavenger 
receptor class B type 1 (SR-b1; NB400-104; Novus 
Biologicals, Centennial, CO), antimouse ABCG5 (gen-
eration described in a previous work(13)), or antimouse 
MDR1-3 (C219; Invitrogen, Carlsbad, CA). Immune 
complexes were detected with a horseradish-per-
oxidase–conjugated secondary antibody (Bio-Rad, 
Hercules, CA), visualized using enhanced chemilumi-
nescence detection reagent (Lumi-light; Roche, Basel, 
Switzerland), and detected using ImageQuant LAS 
4000 (GE Healthcare, Chicago, IL).
RNa ISolatIoN aND qpCR
Total RNA isolation and qPCR was performed as 
described.(9)
QUaNtIFICatIoN oF BIle SaltS 
By HIgH-peRFoRMaNCe lIQUID 
CHRoMatogRapHy
Concentrations of different bile salt species in 
plasma and bile were determined by reverse-phase 
high-performance liquid chromatography (HPLC) as 
described.(2)
lIVeR lIpID ISolatIoN
Liver lipids were isolated using methanol/chloro-
form extraction as described.(14)
aSSayS
Bile salts, choline containing phospholipids, and 
cholesterol in bile were determined enzymatically as 
described.(15) Free cholesterol and total cholesterol 
content of liver lipid isolations were determined using 
a cholesterol cholesterol oxidase/peroxidase amin-
ophenazone assay according to the manufacturer’s 
instruction (catalogus nr. 80106 and 88656; BIOLABO, 
Maizy, France). Total β-hexosaminidase activity in bile 
was determined using a 4-methylumbelliferyl-based 
substrate assay.(16) Determination of changes in fluo-
rescence was performed on a CLARIOstar analyzer 
(BMG-labtech, Offenburg, Germany).
StatIStICal aNalySIS
Data are provided as the median and interquar-
tile range or 95% confidence interval. Differences 
between groups were analyzed using the Mann-
Whitney U test, and statistical significance was con-
sidered when P  <  0.05. To assess whether NTCP 
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inhibition altered the relation between biliary bile 
salt output and biliary cholesterol or phospholipid 
output, linear regression analysis was performed 
on log-transformed data; statistical significant dif-
ferences were considered when either the slope or 
intercepts were determined to be nonequal with 
P  <  0.05. Graph generation and statistical analysis 
were performed using GraphPad Prism (version 7.0; 
GraphPad Software Inc., La Jolla, CA).
Results
To investigate the effects of NTCP inhibition 
on bile formation and biliary bile salt, cholesterol, 
and phospholipid excretion, WT mice were injected 
with the NTCP inhibitor, Myrcludex B, or vehicle 
and bile was collected upon gallbladder cannulation. 
NTCP inhibition resulted in an increase in cho-
lesterol output (Fig. 1A). The higher rate of biliary 
cholesterol excretion after NTCP inhibition was not 
accompanied by changes in biliary bile salt secretion 
(P < 0.0001; Fig. 1B,C), as tested by linear regression 
of log-transformed data. Similar analysis of biliary 
phospholipid output indicated that NTCP inhibition 
also causes an increase in phospholipid output over 
bile salt output (P  <  0.0001, Fig. 1D), even though 
absolute phospholipid output was not significantly 
increased (Supporting Fig. S1A). NTCP inhibition 
did not affect bile flow, plasma bile salt levels, or 
FIg. 1. NTCP inhibition acutely increases biliary cholesterol and phospholipid secretion. Gallbladders of mice were cannulated 1 hour 
after treatment with vehicle or Myrcludex B; standardized 10-minute bile samples were collected and data were plotted in time. 
(A) Total cholesterol and (B) bile salt output (in nmol/min/100 g BW). (C) Cholesterol output and (D) phospholipid output were plotted 
as a function of biliary bile salt output to assess whether this relation was changed by Myrcludex B administration (linear regression was 
performed on log-transformed data and significance was assessed by comparing slopes or intercepts). (E) Biliary bile salt composition 
was quantified using HPLC, expressed as percentage of total conjugated bile acids in bile. (F) β-hexosamindase activity in bile. Data 
are presented as median and interquartile range. White squares/bars indicate the vehicle group, and black squares/bars indicate the 
Myrcludex B group. Differences between groups were analyzed using the Mann-Whitney U test. Asterisk (“*”) indicates P < 0.05; n = 8 
mice/group. Abbreviations: C-BA, conjugated bile acids; Chol., cholesterol; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic 
acid; GDCA, glycodeoxycholic acid; GUDCA, glycoursodeoxycholic acid; PL, phospholipid; TCA, taurocholic acid; TCDCA, 
taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; TαMCA, tauro-alpha-muricholic 
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hepatic mRNA expression levels of small heterodi-
mer partner and cytochrome P450 7a1 (Supporting 
Fig. S1B-E). Altered bile composition after NTCP 
inhibition led to a higher molar ratio of cholesterol to 
bile salts, but did not increase cholesterol saturation 
of bile (calculated using the critical cholesterol satura-
tion tables published previously(17)) given that NTCP 
inhibition also tended to increase the phospholipid to 
bile salt ratio (Supporting Fig. S1F-H). The remark-
able increase of biliary cholesterol and phospholipid 
output over biliary bile salt output prompted further 
investigation of the underlying mechanism.
A few processes have been described that either 
uncouple cholesterol and/or phospholipid output from 
biliary bile salt output or alter the relation between 
biliary bile salt and lipid output.(4,18,19) A potential 
contributor is a change in biliary bile salt species. It 
has been described that hydrophobic bile salt species 
provoke more biliary lipid secretion than hydrophilic 
species.(20) In the case of acute NTCP inhibition, 
however, no change in biliary bile salt composition 
was observed (Fig. 1E). A second potential contrib-
utor is an increased expulsion of lysosomal contents 
into bile, which is quite limited under normal physio-
logical circumstances,(21) upon Myrcludex B injection. 
It has been demonstrated that bile salts directly stim-
ulate lysosomal discharge into bile.(22) Yet, assessment 
of the lysosomal enzyme, β-hexosaminodase, in bile 
indicated that NTCP inhibition did not affect lyso-
somal discharge into bile (Fig. 1F).
A third possible contributor to higher rates of cho-
lesterol and phospholipid excretion is increased activ-
ity of dedicated cholesterol (ATP-binding cassette 
subfamily G member 5/8; ABCG5/8) and phospho-
lipid (ATP-binding cassette subfamily B member 4; 
ABCB4) transporters.(23,24) NTCP inhibition did not 
increase mRNA or protein levels of the ABCG5/8 or 
ABCB4 transporter (Fig. 2A). However, the absence 
of changes in expression level does not exclude a 
change in activity of these transporters. To investi-
gate whether ABCG5/8 serves as a mediator of the 
increase in cholesterol output upon NTCP inhibi-
tion, gallbladder cannulation experiments were per-
formed in Abcg8-deficient mice. Absence of either 
ABCG5 or ABCG8 turns the ABCG5/G8 complex 
fully dysfunctional and results in ~70% reduced cho-
lesterol excretion.(25) Administration of Myrcludex 
B to Abcg8−/− mice did result in a clear increase in 
biliary cholesterol excretion (Fig. 2B). Therefore, 
NTCP inhibition mostly seems to affect ABCG5/ 
8-independent cholesterol secretion, although the 
absolute secretion rates were lower than those in WT 
mice (both in the absence and presence of Myrcludex B; 
Fig. 2B). Biliary phospholipid secretion was increased 
in Abcg8−/− mice as well upon Myrcludex B injection 
(Fig. 2C) and the changes in phospholipid and cho-
lesterol output occurred without any changes in biliary 
bile salt output (Fig. 2D-F) or bile flow (Supporting 
Fig. S2A). Biliary phospholipid secretion relies com-
pletely on ABCB4 activity, and we previously showed 
that NTCP inhibition does not stimulate phospho-
lipid or cholesterol secretion in Abcb4-deficient mice, 
indicating that the induction of lipid secretion by 
Myrcludex B completely relies on ABCB4-mediated 
phospholipid translocation.(9) Hence, these experi-
ments demonstrate that induction of phospholipid and 
cholesterol secretion by Myrcludex B requires activity 
of ABCB4, but increased activity of this transporter is 
unlikely to drive this effect.
Next, we considered that an increased supply of cho-
lesterol and phospholipid to the canalicular membrane 
may occur after NTCP inhibition, leading to increased 
biliary lipid output. It was previously postulated that 
biliary cholesterol excretion originates mainly from 
a (preexisting) hepatic pool of free cholesterol,(26,27) 
given that both microsomal acyl-CoA:cholesterol acyl-
transferase (ACAT) activity and hepatic cholesterol 
ester concentration correlate in a reciprocal manner 
with biliary cholesterol output.(28) The large increase 
in biliary cholesterol output observed upon treatment 
with diosgenin was suggested to be explained by this 
mechanism.(28) However, it was later demonstrated that 
ACAT2 deficiency in mice does not lead to increased 
biliary cholesterol output.(29) We analyzed hepatic 
esterified cholesterol content, but this was not affected 
by Myrcludex B treatment (Supporting Fig. S3A). 
Also, hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme 
A reductase mRNA levels were not affected by 
Myrcludex B treatment (Supporting Fig. S3B). Taken 
together, it does not seem likely that an increased 
supply of cholesterol to the canalicular membrane is 
derived from larger intracellular stores.
Enhanced uptake of cholesterol and phospholipids 
present in lipoproteins could theoretically stimulate 
both cholesterol and phospholipid excretion. It was 
demonstrated that especially high-density lipoprotein 
(HDL)-derived cholesterol ends up rapidly in bile 
in rodents.(30) The uptake process is likely mediated 
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by the scavenger receptor class B type 1 (SCARB1/
SR-B1), the main receptor for HDL. This receptor 
has also been shown to be able to mediate biliary 
cholesterol secretion independent of Abcg5/8.(31,32) In 
addition, liver-specific overexpression of Sr-bI in mice 
also stimulates biliary phospholipid output.(31) To test 
the potential contribution of SR-B1/HDL–derived 
lipids to the biliary phenotype of NTCP inhibition, 
Sr-bI–deficient mice were injected with Myrcludex B 
or vehicle and gallbladder cannulation was performed. 
Myrcludex B induced an absolute increase in bili-
ary cholesterol output of >50% in Sr-bI−/− mice, but 
this did not reach statistical significance (Fig. 3A). 
The effects of NTCP inhibition on phospholipid 
secretion were clearly preserved in the Sr-bI−/− mice 
(Fig. 3B) and bile salt output itself was not affected 
(Fig. 3C). Similar to WT and Abcg8−/− mice, Myrcludex 
B treatment increased cholesterol and phospholipid 
FIg. 2. Increased biliary cholesterol secretion after NTCP inhibition is largely independent of ABCG5/8. (A) Hepatic mRNA and 
protein expression of Abcg5, Abcg8, and Abcb4 in WT mice. RNA expression is compared to the geometric mean of reference genes 36b4 
and Tbp. Protein levels were compared to the sodium/potassium ATPase (n = 3/group). (B) Cholesterol output (in nmol/min/100 g BW) 
in Abcg8−/− mice. One 10-minute interval of biliary cholesterol output is compared between WT and Abcg8−/− mice. (C) Phospholipid 
and (D) bile salt output into bile were determined in Abcg8−/− mice. (E) Cholesterol output and (F) phospholipid output were plotted 
as a function of biliary bile salt output (linear regression was performed on log-transformed data and significance was assessed by 
comparing slopes or intercepts). Data are presented as median and interquartile range. White squares/bars indicate the vehicle group, 
and black/gray squares/bars indicate the Myrcludex B group. Differences between groups were analyzed using the Mann-Whitney U 
test. Asterisk (“*”) indicates P < 0.05; n = 8 mice/group. × Indicates statistical outlier in Tukey plot. Abbreviations: Chol., cholesterol; 
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output relative to bile salt output (P  =  0.0002, 
Fig. 3D; P < 0.0001, Fig. 3D,E) and without changing 
bile flow (Supporting Fig. S4A). These experiments 
do not support the hypothesis that increased uptake of 
HDL-derived cholesterol and phospholipids explains 
the increase in biliary cholesterol and phospholipid 
secretion upon NTCP inhibition. In accord with this 
conclusion is the absent change in expression of Sr-bI 
in livers of Myrcludex B–treated WT mice (Fig. 3F).
Given that neither of the investigated mecha-
nisms provided an explanation for the findings of the 
current study, we propose a concept to explain why 
NTCP inhibition induces secretion of biliary lip-
ids. We considered that blockade of NTCP induces 
FIg. 3. Increased biliary cholesterol and phospholipid secretion is not mediated by SR-B1. (A) Cholesterol output, (B) phospholipid 
output, and (C) bile salt output into bile (in nmol/min/100 g BW) in Sr-bI−/− mice. (D) Cholesterol output and (E) phospholipid output 
were plotted as a function of biliary bile salt (linear regression was performed on log-transformed data and significance was assessed by 
comparing slopes or intercepts). (F) Hepatic mRNA and protein expression level of Sr-bI in WT mice. RNA expression is compared 
to the geometric mean of reference genes 36b4 and Tbp. Protein levels were compared to the sodium/potassium ATPase (n = 3/group). 
Data are presented as median and interquartile range. White squares/bars indicate the vehicle group, and black/gray squares/bars 
indicate the Myrcludex B group. Differences between groups were analyzed using the Mann-Whitney U test. Asterisk (“*”) indicates 
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a shift in bile salt uptake from mainly periportal 
to mainly pericentral hepatocytes. Bile salt uptake 
by hepatocytes displays a clear zonal distribution 
where periportal hepatocytes encounter the highest 
concentration of bile salts and contribute most to the 
clearance of intestine-derived bile salts under physi-
ological conditions(33) (Fig. 4A,B). Administration of 
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vehicle-treated WT mice demonstrates this zonal dis-
tribution, given that canalicularly located fluorescent 
bile salts are mainly restricted to the canaliculi around 
portal veins (Fig. 4B). Thus far, it has been described 
that only at high bile salt loads, for example, upon 
infusion with TC, pericentral hepatocytes also con-
tribute to bile salt uptake.(33) We hypothesized that 
upon NTCP inhibition, bile salts will reach pericentral 
hepatocytes also at low bile salt loads. During NTCP 
inhibition, hepatic bile salt uptake is maintained by 
OATP proteins and therefore biliary bile salt output 
is unaffected.(2) OATP proteins are predominantly 
expressed in pericentral regions of the liver lobules,(34) 
contributing to a shift in bile salt uptake from peri-
portal to pericentral regions during NTCP inhibition. 
To visualize a shift in zonated bile salt uptake upon 
NTCP inhibition, we administered the fluorescent 
bile salt, tauro-nor-HCA-24-DBD, to Myrcludex B–
treated WT mice and to Ntcp−/− mice. Of note, tauro- 
nor-HCA-24-DBD is transported by both NTCP 
and OATP proteins.(35) In contrast to periportal dis-
tribution of the fluorescent bile salts in vehicle-treated 
mice (Fig. 4B), cytoplasmic and canalicular distribu-
tion of bile salts in both Myrcludex B–treated WT 
mice and Ntcp−/− mice extended beyond the peripor-
tal zone toward the central zone (Fig. 4C,D). These 
experiments indicate that a significant portion of bile 
salt uptake during NTCP inhibition is mediated by 
more pericentral hepatocytes. We hypothesized that 
because of countercurrent bile flow, increased pericen-
tral bile salt uptake will lead to a longer exposure, of a 
larger area of the canalicular membrane, to bile salts, 
allowing for higher biliary lipid secretion (Fig. 4C).
To assess whether altered zonated hepatic bile salt 
uptake can contribute to an increase in biliary lipid 
secretion, we analyzed the relation between biliary 
cholesterol and bile salt secretion in two models with 
zonation-related phenotypes. First, we reassessed a 
TC-infusion experiment, which was previously per-
formed in WT and Atp11c-deficient mice.(12) Atp11c-
deficient mice are a model with a zonation difference 
in bile salt uptake given that basolateral bile salt 
uptake transporters are absent in the pericentral region 
restricting bile salt uptake to periportal regions, where 
NTCP expression is maintained in the periportal 
hepatocyte (Fig. 4E).(12,36) In this experiment, the rela-
tion between biliary cholesterol and bile salt levels was 
not significantly different between Atp11c-deficient 
mice and WT littermates under conditions where 
the periportal region predominates uptake (before 
TC infusion). However, infusion of TC revealed an 
attenuated increase in cholesterol (P = 0.0023; but not 
phospholipid) secretion (Fig. 4F) in Atp11c-deficient 
mice compared to control littermates, whereas bile salt 
output was similar. These results suggest that if peri-
central hepatocytes become involved in hepatic bile 
salt uptake, more cholesterol may be secreted into bile, 
even at similar bile salt output rates.
Second, we assessed the consequences of Myrcludex 
B administration on biliary output of bile salts and 
lipids in a model where biliary bile salt excretion 
is largely limited to pericentral hepatocytes upon 
NTCP inhibition. For this purpose, hOATP1B1 
Oatp1a/1b−/− mice were used. In these mice, the 
murine Oatp1a/1b-class proteins are lacking and bile 
salt uptake is completely dependent upon NTCP.(11) 
The human OATP1B1 protein was introduced into 
these mice and facilitates the uptake of Oatp1a/1b 
substrates such as bilirubin and steroid hormones.(37) 
The human OATP1B1 transports bile salts, but 
only to a very limited extent.(2) In the hOATP1B1 
Oatp1a/1b−/− mice, bile flow, bile salt output, and 
FIg. 4. NTCP inhibition shifts hepatic bile salt uptake to pericentral hepatocytes, which links to higher biliary phospholipid and 
cholesterol secretion rates. (A) Graphic depicting exposure of the canalicular membrane to bile salts and zonated bile salt uptake in 
physiological situation. (B) Image of a liver of an WT mouse 5 minutes after injection with the f luorescent bile salt, tauro-nor-HCA-
24-DBD. (C) Proposed mechanism of increased biliary lipid secretion after NTCP inhibition showing increased intracanalicular 
exposure to bile salts attributed increased pericentral bile salt uptake. (D) Images of livers of a Myrcludex B–treated WT mouse 
(top) and a Ntcp−/− mouse (bottom) 5 minutes after injection with the f luorescent bile salt, tauro-nor-HCA-24-DBD. (E) Graphic 
depicting zonated bile salt uptake and intracanalicular exposure in Atp11c-deficient mice. (F) Cholesterol and phospholipid output 
as function of bile salt output in TC-infused Atp11c-deficient mice (linear regression was performed on log-transformed data and 
significance was assessed by comparing slopes or intercepts). White squares indicate WT mice; gray squares indicate Atp11c-deficient 
mice. Differences between groups were analyzed using the Mann-Whitney U test. Asterisks (“*”) indicate P  < 0.05; n = 5-7 WT 
versus Atp11c. Abbreviations: Chol., cholesterol; KO, knockout; MyrB, Myrcludex B; PL, phospholipid; tauro-nor-HCA-24-DBD, 
N-(24-(7-(4-N,N-dimethylaminosulfonyl-2,1,3-benzoxadiazole))amino-3alpha,7alpha,12alpha-trihydroxy-27-nor-5beta-cholestan- 
26-oyl)-2′-aminoethanesulfonate.
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phospholipid output were dramatically reduced after 
Myrcludex B administration (Fig. 5A-C). Cholesterol 
output, on the other hand, was maintained after 
Myrcludex B administration (Fig. 5D). Myrcludex B 
treatment increased the proportional secretion of both 
cholesterol and phospholipid relative to bile salt out-
put (P = 0.0154, Fig. 5E; P = 0.0039, Fig. 5F). When 
NTCP is inhibited and Oatp-mediated uptake is 
virtually absent, hepatic bile salt uptake is essentially 
abolished and only newly synthesized bile salts are 
secreted into the biliary tree. Bile salt synthesis occurs 
primarily in central hepatocytes.(38) Given that the 
bile salts are secreted by the central hepatocytes, the 
canalicular membrane of hepatocytes is exposed for a 
longer period of time to these bile salts, allowing for 
extraction of more cholesterol per amount of bile salt 
secreted. The results of these two models are in line 
with the proposed stimulatory role of shifting biliary 
bile salts from the periportal to the pericentral area on 
biliary cholesterol secretion.
Discussion
Taken together, we demonstrated that NTCP inhi-
bition induces a greater contribution of pericentral 
hepatocytes to total hepatic bile salt uptake, which links 
to the observed increase in biliary cholesterol secretion. 
We postulate that the increase in pericentral bile salt 
processing, combined with the countercurrent bile flow, 
increases the exposure (time and area) of the canalicular 
membrane to intracanalicular bile salts (Fig. 4D). The 
potential importance of exposure time was already pro-
posed by Verkade et al., who suggested that prolonged 
exposure of canalicular membranes to intracanalicular 
bile salts, attributed to reduced bile-salt–independent 
bile flow, allows for more phospholipids and choles-
terol molecules to be excreted per bile salt molecule.(39) 
Our study suggests that increased pericentral secretion 
of bile salts plays a similar role in increasing exposure.
In conclusion, we discovered that NTCP inhibition 
in mice induces biliary cholesterol and phospholipid 
FIg. 5. Total inhibition bile salt uptake reduces biliary bile salt and phospholipid output, but maintains biliary cholesterol output. 
(A) Bile f low, (B) biliary bile salt output, (C) biliary phospholipid output, and (D) biliary cholesterol output into bile (in nmol/min/100 g 
BW) in hOATP1B1 Oatp1a/1b−/− mice. (E) Cholesterol output and (F) phospholipid output were plotted as a function of biliary bile 
salt (linear regression was performed on log transformed data and significance was assessed by comparing slopes or intercepts). Data 
are presented as median and interquartile range. White squares/bars indicate the vehicle group, and black/gray squares/bars indicate 
the Myrcludex B group. Differences between groups were analyzed using the Mann-Whitney U test. Asterisk (“*”) indicates P < 0.05; 
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excretion, without affecting biliary bile salt output 
rates. Changes in bile salt hydrophobicity, lysosomal 
discharge, increased expression of transporter proteins, 
or stimulated uptake of plasma lipids were excluded 
as potential contributors to the increased biliary lipid 
output. Instead, a shift of bile salt uptake from peri-
portal toward pericentral hepatocytes is the most likely 
the driving force for the increase in biliary cholesterol 
and phospholipid output. As such, the current study 
provides a view on the concept of bile-salt–driven bil-
iary lipid secretion, showing that location of hepatic 
bile salt uptake is an important contributing factor.
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